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ABSTRACT
ABCG2 encodes the breast cancer resistance protein (BCRP), an
efflux membrane transporter important in the detoxification of
xenobiotics. In the present study, the basal activity of the ABCG2
promoter in liver, kidney, intestine, and breast cell lines was examined
using luciferase reporter assays. The promoter activities of reference
and variant ABCG2 sequences were compared in human hepato-
cellular carcinoma cell (HepG2), human embryonic kidney cell
(HEK293T), human colorectal carcinoma cell (HCT116), and human
breast adenocarcinoma cell (MCF-7) lines. The ABCG2 promoter
activity was strongest in the kidney and intestine cell lines. Four
variants in the basal ABCG2 promoter (rs76656413, rs66664036,
rs139256004, and rs59370292) decreased the promoter activity by
25%–50% in at least three of the four cell lines. The activity of these
four variants was also examined in vivo using the hydrodynamic tail
vein assay, and two single nucleotide polymorphisms (rs76656413 and
rs59370292) significantly decreased in vivo liver promoter activity by
50%–80%. Electrophoretic mobility shift assays confirmed a reduc-
tion in nuclear protein binding to the rs59370292 variant probe,
whereas the rs76656413 probe had a shift in transcription factor
binding specificity. Althoughboth rs59370292 and rs76656413 are rare
variants in all populations, they could contribute to patient-level
variation in ABCG2 expression in the kidney, liver, and intestine.
Introduction
The breast cancer resistance protein (BCRP) ABCG2 is an efflux
membrane transporter and part of the ATP-binding cassette (ABC)
transporter family. It transports a variety of dietary toxins, endogenous
nutrients, and pharmaceutical compounds (Ni et al., 2010). BCRP is
expressed in the side population of hematologic stem cells, endothelium
of veins and capillaries (including in the brain), intestinal and colon
epithelium, placental syncytiotrophoblasts, ducts and lobules of the
breast, the bile canalicular membrane of hepatocytes, and to a lesser
extent in renal cortical tubules (Robey et al., 2009). BCRP is essential for
detoxification processes, the transport of nutrients into milk, and the
protection of vital organs and tissues like the brain, fetus, prostate, and
eye (Leslie et al., 2005). Interindividual expression of ABCG2mRNA is
highly variable, with reports of 500-fold differences among human livers
without detectable copy number variation (Poonkuzhali et al., 2008),
1000-fold differences in leukemic blast cells (Ross et al., 2000) and 1.8-
fold to 78-fold differences in human intestine (Zamber et al., 2003;
Urquhart et al., 2008). Additionally, high ABCG2 expression has been
linked to decreased disease-free survival in cancer (Mao and Unadkat,
2015). Understanding the mechanisms that regulate the expression of
ABCG2 can help to predict cancer outcomes, drug response, and
toxicity. These mechanisms could become clinical targets of epigenetic
inhibitors to downregulate transporter expression and enhance the
efficacy of pharmacotherapy (Chen et al., 2016).
BCRP is transcribed by ABCG2, which spans over 66 kilobases on the
anti-strand of chromosome 4q22 (Allikmets et al., 1998). The basal
ABCG2 promoter is a TATA-less promoter identified as the 312 base
pairs upstream of the transcription start site (TSS) (Bailey-Dell et al.,
2001), whereas the 59 promoter regulatory region has been described
as .100 kilobases (Poonkuzhali et al., 2008). The basal promoter
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includes a CCAAT box and numerous binding sites for specificity protein
1 and activator proteins 1 and 2 (Fig. 1) (Bailey-Dell et al., 2001). The
proximal promoter of ABCG2 has a functional aryl hydrocarbon receptor
response element (Tan et al., 2010; To et al., 2011) that overlaps with
progesterone elements (Wang et al., 2008b) and estrogen response
elements (Ee et al., 2004) (Fig. 1). It also has a nuclear factor-kB response
element that works in concert with estrogen to increase ABCG2
expression (Pradhan et al., 2010), a hypoxia-inducible factor 1a response
element (Krishnamurthy et al., 2004), and an antioxidant response
element (ARE) (Singh et al., 2010) (Fig. 1). A large cytosine-phospho-
guanine (CpG) island coversmost of theABCG2 proximal promoter (Fig.
1) (Tan et al., 2010). To date, there are no systematic evaluations of the
effect of genetic variation on the activity of the ABCG2 promoter.
Genetic polymorphisms in the proximal promoter of transporter genes
have been linked to variation in gene expression (Ha Choi et al., 2009;
Hesselson et al., 2009; Li et al., 2009; Yee et al., 2009). Additionally,
genetic variation in promoters for transporters and enzymes have been
linked to adverse drug reactions (Innocenti et al., 2004; Wang et al.,
2008a; Kenna et al., 2009; McLeod et al., 2010; Toffoli et al., 2010).
Previous studies of the effect of regulatory variants on ABCG2
expression (Zamber et al., 2003; Poonkuzhali et al., 2008; Eclov et al.,
2017a) have only considered regions outside the primary promoter.
In the present study, the basal activity of the major ABCG2 promoter
(2499 to +21 bp relative to the TSS) was investigated in transiently
transfected kidney, liver, intestine, and breast cell lines. The activity of
11 variant ABCG2 promoters was characterized in these same cell lines
to identify SNPs that alter ABCG2 promoter activity. Rare variants were
included in this study because they have recently been shown to
contribute significantly to individual gene expression profiles (Li et al.,
2014). Variants that caused significant in vitro reductions in ABCG2
promoter activity were also tested in the mouse hydrodynamic tail vein
assay for their effect on in vivo promoter activity. Electrophoretic
mobility shift assays (EMSAs) were performed on SNPs with signifi-
cantly altered in vivo activity to understand how sequence affects
transcription factor binding.
Materials and Methods
Chemicals and Materials. The vectors pGL4.11b [luc2P], pGL4.74 [hRluc/
TK], pGL4.13 [luc2/SV40], and the Dual-Luciferase Reporter Assay System
were purchased from Promega (Madison, WI). The human embryonic kidney
(HEK293T/17), human colorectal carcinoma (HCT116), human hepatocellular
carcinoma (HepG2), and human breast adenocarcinoma (MCF-7) cell lines were
Fig. 1. Schematic of the ABCG2 promoter region. The genomic region chr4:89079997-89080517 (hg19) with red boxes indicating location of basal transcription factors and the
TSS, and blue boxes indicating locations for nuclear factor-kB response element (NFkBRE), hypoxia response element (HRE), aryl hydrocarbon response element (AhRE), estrogen
response element (ERE), progesterone response element (PRE), and ARE. The promoter is also covered by a CpG island, which is indicated by a dark green bar. The binding of
transcription factors determined by ChIP-seq from ENCODE data is indicated by the horizontal bars, with the length and shading of the bar indicating the breadth and strength of the
peak. Within the bar, a light green box indicates the site of a canonical motif for the corresponding factor. Cell lines for peaks are indicated by letters, as follows: K, K562; H, HeLa-
S3; L, HepG2; A/a, A549; p, PBDE; M/m, MCF-7; 1, H1-hourESC; n, NB4. Finally, the location and rs number for SNPs reported in dbSNP 138 are indicated.
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purchased from the American Type Culture Collection (Manassas, VA). High-
glucose Dulbecco’s modified Eagle’s medium, Opti-MEM, and Lipofectamine
2000 were purchased from Invitrogen (Carlsbad, CA). Penicillin and streptomy-
cin were purchased from the University of California San Francisco (UCSF) Cell
Culture Facility (San Francisco, CA). Phusion High-Fidelity DNA Polymerase,
NheI, HindIII, and DpnI, were purchased from New England BioLabs (Ipswich,
MA). Fetal bovine serum (FBS) (Axenia BioLogix, Dixon, CA), GenElute HP
Endotoxin-Free Maxiprep Kits (Sigma-Aldrich, St. Louis, MO), Improved
Minimum Essential Medium without phenol red (Mediatech Inc., Manassas, VA),
TransIT EE In Vivo Gene Delivery System (Mirus Bio, Madison,WI), CD1mice
(Charles River Laboratories, Wilmington, MA), PolyJet DNA In Vitro Trans-
fection Reagent (SignaGen Laboratories, Rockville, MD), Odyssey EMSABuffer
Kit (LI-COR, Lincoln, NE), HepG2 Nuclear Extract (Abcam, Cambridge, MA),
and PfuTurbo DNA Polymerase (Agilent Technologies, Santa Clara, CA) were
purchased from the indicated manufacturers.
ABCG2 Promoter Plasmid Construction. A 524-bp region of the ABCG2
promoter (chr4:89079995-89080518, hg19) was polymerase chain reaction (PCR)
amplified using the forward primer 59-TCAGGCTAGCAAGCATCCACTTTCT-
CAGA-39 and reverse primer 59-TTATAAGCTTCAGGCAGCGCTGACAC-
GAA-39. This region included the proximal promoter (2312 bp upstream of the
TSS), adjacent transcription factor response elements, and the CpG island that
extends to ;500 bp upstream of the TSS (Fig. 1) (Bailey-Dell et al., 2001). The
sequences for restriction sites NheI and HindIII were added to the forward and
reverse primers, respectively (underlined in the above sequences). The region was
amplified from human placenta genomic DNA using PfuTurbo DNA polymerase
following the manufacturer protocol. PCR conditions were 95C for 2 minutes,
followed by 35 cycles of 30 seconds at 95C, 30 seconds at 60C, and 1 minute at
68C, then a final extension of 10 minutes at 72C. The 542-bp PCR product was
gel purified, enzyme digested, and ligated into the pGL4.11b vector. The reaction
was purified and transformed into competent cells, and colonies containing the
reverse promoter (forward transcription direction) orientation were isolated. DNA
for pGL4.11b promoter plasmids and empty pGL4.11b, pGL4.74, and pGL4.13
vectors were isolated using the GenElute HP Endotoxin-Free Maxiprep Kit
(Sigma-Aldrich) following the manufacturer protocol.
Genetic Analysis of ABCG2 Promoter Region. SNPs in the ABCG2
promoter region were retrieved for all available ethnic populations from publicly
available databases, including 1000Genomes (phase 1 release February 14, 2012)
(Abecasis et al., 2010), dbSNP build 137, and HapMap release 28 (Frazer et al.,
2007). These SNPs were combined with sequencing results from the ABCG2
promoter region (2674 to +85 bp) of the SOPHIE cohort and reported in the
Pharmacogenetics of Membrane Transporter Database (UCSF) (Hesselson et al.,
2009; Kroetz et al., 2010). Haplotypeswere determined by downloading genotype
and information files from the 1000 Genomes browser (phase 1 release May 21,
2011) for all available ethnic groups combined and analyzed with Haploview
version 4.2 (Barrett et al., 2005).
Site-Directed Mutagenesis. ABCG2 promoter SNPs were introduced into the
reference promoter plasmid using the Phusion High-Fidelity DNA Polymerase,
following the manufacturer protocol. Reaction conditions for all site-directed
mutagenesis primers (Supplemental Table 1) except rs139256004 are as follows:
an initial cycle for 30 seconds at 98C, followed by 20 cycles for 10 seconds at
98C, the primer pair melting temperature for 30 seconds and 3 minutes at 72C,
then a final extension for 10 minutes at 72C. The deletion SNP rs139256004 was
introduced into the ABCG2 promoter using a special protocol for deletion
mutagenesis (Liu and Naismith, 2008). The PCR components were the same as
described above with the following PCR conditions: an initial cycle at 95C for
5 minutes; then 12 cycles at 95C for 1 minute, 45C for 1 minute, and 72C for
9 minutes; with a final cycle for 1 minute at 36C and 30 minutes at 72C.
Promoter SNP rs57327643 was also attempted via this protocol, but no colonies
were isolated. The site-directed mutagenesis PCRs were digested with the DpnI
enzyme, purified, and transformed into competent cells. Plasmids were isolated
and sequenced to confirm the presence of the SNP. All DNA used for the in vitro
and in vivo luciferase assays was endotoxin free.
Cell Culture, Transfections, and Luciferase Assays. HEK293T/17,
HCT116, and HepG2 cells were grown in high-glucose Dulbecco’s modified
Eagle’s medium supplemented with 10%FBS, 100U/ml penicillin and 0.1 mg/ml
streptomycin. The MCF-7 cell line was grown in Improved Minimum Essential
Medium without phenol red, supplemented with 10% FBS, 100 U/ml penicillin,
and 0.1 mg/ml streptomycin. All cell lines were grown in a 5% CO2 incubator at
37C. Transient transfections were performed as previously described (Eclov
et al., 2017b) and the firefly and Renilla luciferase activity of cell lysates were
measured using the Dual-Luciferase Reporter Assay System (Promega) in a
GloMax 96-Microplate Dual Injector Luminometer (Promega) following the
manufacturer protocol. Each experiment included the empty pGL4.11b vector as
the negative control and the pGL4.13 vector as the positive control. Promoter
plasmid firefly activity was normalized to Renilla activity and then displayed
relative to the normalized activity of empty pGL4.11b.
Hydrodynamic Tail Vein Assay. Positive in vitro variant promoter plasmids
were screened for their effect on in vivo promoter activity through the
hydrodynamic tail vein injection as previously described (Eclov et al., 2017b).
Briefly, 10 mg of promoter plasmid or the ApoE (Simonet et al., 1993) positive
control liver enhancer, along with 2 mg of pGL4.74 was injected into the tail vein
of four to five male CD1 mice (Charles River Laboratories) weighing 21–25 g
using the TransIT EE In Vivo Gene Delivery System (Mirus Bio) following the
manufacturer protocol. After 24 hours, liver lysates harvested from the euthanized
mice were measured for firefly and Renilla luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega) following the manufacturer
protocol in a Synergy 2 (BioTek Instruments, Winooski, VT) microplate reader.
The firefly activity in each sample was normalized to Renilla activity and
expressed as fold activation relative to pGL4.11b. All mouse work was approved
by the UCSF Institutional Animal Care and Use Committee.
Electrophoretic Mobility Shift Assay. EMSAs were performed using a 2.5
nM59 IRDye 700 (LI-COR)–labeled probe, incubatedwith 5mg ofHepG2 nuclear
extract using the Odyssey EMSA Buffer Kit (LI-COR) as previously described
(Eclov et al., 2017a). Competition assays were performed by adding a 40-fold
molar excess of unlabeled reference oligonucleotide. DNA/protein complexeswere
separated from free probe by gel electrophoresis and imaged using the LI-COR
system (Odyssey). Transcription factors that bound over the ABCG2 promoter and
its SNPs were obtained from ChIP-seq data from the Encyclopedia of DNA
Elements (ENCODE) database (ENCODE Project Consortium, 2011).
Statistical Analysis. Normalized promoter activity is expressed relative to
pGL4.11b. Basal forward and reverse promoter activity in the HEK293T and
HepG2 cell lines were tested for significance (P , 0.05) from empty pGL4.11b
vector with an analysis of variance (ANOVA) followed by a Bonferroni’s
multiple-comparison t test. Basal promoter activity in the HCT116 and MCF-7
cell lines was tested for significance (P, 0.05) from the empty pGL4.11b vector
with a Student’s t test. Variant ABCG2 promoter sequences selected for in vivo
testingwere significantly different (P, 0.05) from the reference promoter in three
of four cell lines. Variant promoter plasmids tested in vitro or in vivo were tested
for significance (P, 0.05) from the reference ABCG2 promoter with an ANOVA
followed by a Bonferroni’s multiple-comparison t test. The reference promoter
and the ApoE enhancer were tested for difference from the empty vector sequence
in vivo using an unpaired Student’s t test. All statistics were run using the
GraphPad Prism 5 program (GraphPad Software, San Diego, CA).
TABLE 1
ABCG2 promoter SNPs
Variant Positiona DNTb
MAF (%)c
AFR AMR EAS EUR SAS
rs61181041 284 C . T NR NR 0.01 NR NR
rs61535534 2151 G . C 0.00 0.00 0.00 0.03 0.00
rs76656413 2169 C . T 0.00 0.00 1.00 0.00 0.00
rs57327643 2266 AGTGTTT .- 1.20 3.70 0.00 7.60 5.00
rs66664036 2267 -. G NR 3.40 NR NR NR
rs139256004 2267 GTTA.- 2.80 0.10 0.00 0.00 0.00
rs2231134 2307 G . C 0.20 2.60 0.00 4.10 0.10
rs45604438 2340 G . T 6.80 0.60 0.00 0.20 0.00
rs58132660 2400 G . A 0.20 0.10 0.01 0.00 0.01
rs142365584 2424 C . G 0.00 0.10 0.00 0.00 0.0
rs59370292 2435 C . T NR NR 0.80 NR NR
rs59172759 2483 T . A 5.50 0.30 0.00 0.20 3.60
AFR, African American; AMR, Mixed American; EAS, Eastern Asian; EUR, European; NR,
not reported; NT, nucleotide; SAS, South Asian.
aSNP position is noted relative to the TSS.
bNucleotide change of the reference allele to the variant allele on the anti-strand as obtained
from the UCSF genome browser.
cMAF for AFR, AMR, EAS, EUR, and SAS reported in dbSNP release 37 by 1000 Genomes
or PMT.
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Results
Genetic Polymorphisms of the ABCG2 Promoter. Twelve variants
(Table 1) were obtained for the ABCG2 promoter region from publicly
available databases and from sequencing of the SOPHIE cohort. Of the
12 variants, rs57327643, rs2231134, rs45604438, and rs59172759 had a
minor allele frequency (MAF) above 4% in at least one ethnic population
(Table 1). The ABCG2 promoter variants included the single nucleotide
insertion rs66664036 and two multiple–base pair deletions, rs57327643
and rs139256004. Attempts to construct the rs57327643 variant pro-
moter plasmid were unsuccessful, and this variant was not evaluated in
the functional assays. There was no notable linkage disequilibrium
between variants in the ABCG2 promoter.
Activity of the ABCG2 Promoter In Vitro. The activity of the
ABCG2 promoter sequence (chr4:89079947-89080567, hg19), cloned
into the firefly luciferase reporter vector pGL4.11b, was investigated in
transiently transfected HEK293T, HepG2, HCT116, and MCF-7 cell
lines (Fig. 2). This region includes the basal promoter of ABCG2 and the
structural elements displayed in Fig. 1. The reverse ABCG2 promoter
activity was strongest in HEK293T and HCT116 cells, with average
activation of 11-fold and 17-fold, respectively; in theHepG2 andMCF-7
cells promoter activity was weaker, with average activation of 2.4-fold
and 1.5-fold, respectively (Fig. 2).
Variant ABCG2 Promoter Activity In Vitro. The effect of
11 variants (Table 1) on the basal ABCG2 promoter activity was
investigated in all four cell lines. Five variants had significantly
decreased activity in HEK293T cells; two of them (rs59370292 and
rs76656413) had over a 50% decrease in promoter activity (P , 0.05,
Fig. 2A). Of the three variants with decreased activity in HepG2, only
rs76656413 had over a 50% decrease (P , 0.05, Fig. 2B). In HCT116
cells, five variants had decreased activity, including a 50% decrease with
rs76656413 and rs139256004 and .75% decrease with rs59370292
(P , 0.05) (Fig. 2C). All four variants with significant decrease in
activity in MCF-7 cells, (rs76656413, rs66664036, rs139256004, and
rs59370292) had at least a 50% decreased activity (P . 0.05, Fig. 2D).
The rs66664036 and rs139256004 variants both had 25%–50% de-
creased activity in three of the four cell lines and the rs76656413 SNP
had over a 50% decreased activity in all four of the cell lines. The
rs59370292 SNP was the most detrimental variant in both HEK293T
and HCT116 cell lines with an almost 75% decreased activity; it also had
25%–50% decreased activity in HepG2 and MCF-7 cells. Because of
their decreased promoter activity in at least three of four cell lines,
rs66664036, rs139256004, rs76656413, and rs59370292 were chosen
for follow-up in the in vivo hydrodynamic tail vein injection assay.
Variant ABCG2 Promoter Activity In Vivo. Four variants (two
SNPs, one single-base insertion, and a four-base deletion) were screened
for their effect on in vivo ABCG2 promoter activity using the
hydrodynamic tail vein injection assay. In this assay, the ApoE liver
enhancer (Simonet et al., 1993) positive control had more than 200-fold
Fig. 2. Effect of promoter variants in vitro. Luciferase assay of ABCG2 reference and variant promoter sequences was measured in transiently transfected kidney (HEK293T)
(A), liver (HepG2) (B), intestine (HCT116) (C), and breast (MCF-7) (D) cell lines. Promoter activity is expressed as the ratio of firefly to Renilla luciferase activity
normalized to empty pGL4.11b. Data are expressed as box-and-whisker plots of mean values from multiple experiments (N = 4–8 biologic replicates with three to six wells
per construct). Differences between reference and variant promoter constructs were tested by an ANOVA followed by a post hoc Bonferroni multiple-comparison t test: *P,
0.05.
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increase in activation over empty vector. The ABCG2 promoter plasmid
exhibited a strong 35-fold activation over pGL4.11b. Two of the four
promoter variants significantly decreased promoter activity in vivo (P,
0.05, Fig. 3). The rs59370292 SNP decreased promoter activity over
80%, whereas rs76656413 resulted in a 70% decrease in promoter
activity in vivo.
Variant ABCG2 Promoter DNA Binding to Nuclear Protein. The
ABCG2 variants rs59370292 and rs76656413 were tested for alteration
in binding to nuclear proteins via EMSA. Reference DNA probes at
these SNP locations showed strong HepG2 nuclear protein binding with
specific DNA/protein bands susceptible to competition by unlabeled
oligonucleotide probes (Fig. 4). The rs59370292 SNP showed reduced
binding to HepG2 nuclear proteins compared with its reference DNA
sequence (Fig. 4A). The rs76656413 SNP lost the specific DNA/protein
binding of the reference sequence, but gained a separate DNA/protein
binding interaction (Fig. 4B).
Discussion
Previous research has highlighted the role of the ABCG2 promoter in
the regulation of BCRP expression (Robey et al., 2009). Although the
ABCG2 proximal promoter has many transcription factor response
elements, variants within the ABCG2 promoter have not yet been
associated with its mRNA levels. In this study, the activity of theABCG2
promoter and the effects of variants on that activity were investigated in
liver, kidney, intestine, and breast cell lines. Variants with a consistent
in vitro effect on ABCG2 promoter activity were tested for their effect in
the in vivo mouse tail vein assay. The ABCG2 promoter was highly
active in intestinal and kidney cell lines, and hadmedium activity in liver
and low activity in breast cell lines. Despite modest in vitro liver activity,
the ABCG2 promoter had strong in vivo liver activity. These results
correlate with high expression of ABCG2 in intestine and liver andmore
moderate expression of ABCG2 in kidney (Maliepaard et al., 2001). In
contrast, the low promoter activity in the MCF-7 cells is inconsistent
with the high expression of ABCG2 in breast tissue (Maliepaard et al.,
2001).
In earlier work, luciferase assays on the2628/+362 ABCG2 promoter
segment indicated suppressed activity in MCF-7 cells, whereas
the 2312/+362 promoter segment was highly active. It is possible that
a suppressor element within the 2499 to 2312 segment reduces the
activity of our ABCG2 promoter construct in MCF-7 cells (Bailey-Dell
et al., 2001). An interferon-gamma activated sequence at 2448/2422
has been shown to increase the ABCG2 promoter activity upon
stimulation of the Janus kinase 2/signal transducer and activator of
transcription 5 (STAT5) pathway by prolactin (Wu et al., 2013). STAT5
is well documented for its importance in regulating the expression of
genes essential for mammary development and lactogenesis (Watson,
2001). Naturally occurring dominant-negative isoforms of STAT5 have
also been shown to suppress the transcriptional activity of the estrogen
receptor in MCF-7 cells (Yamashita et al., 2003). Previous research has
shown discordant results in the ability of the ABCG2 promoter to be
upregulated in MCF-7 cells when treated with 17b-estradiol (Imai et al.,
2005; Yasuda et al., 2009). Therefore, it is possible that without
stimulation of the STAT5 pathways, there is a suppressive factor bound
between 2499 and 2312 of the ABCG2 promoter in MCF-7 cells that
inhibits promoter activity. This indicates a fragile and complex network
of transcription factors that bind to the ABCG2 promoter and regulate its
expression in a cell/tissue contextual manner.
Two of the ABCG2 promoter variants (rs76656413 and 59370292)
decrease the hepatic activity of theABCG2 promoter in vitro and in vivo.
A third variant, rs66664036, significantly decreased in vitro promoter
activity in a hepatic cell line and showed an almost 50% decrease in
in vivo hepatic promoter activity that did not reach significance. Similar
to in vitro and in vivo analysis of enhancer variants in ABCG2 and other
pharmacogenes (Kim et al., 2011; Eclov et al., 2017a,b), there was not a
complete concordance between promoter assays in cell lines and results
from the in vivo assay. Discordance between in vitro and in vivo results
might reflect differences between human and murine transcription
factors, and highlights one of the limitations of the tail vein assay. This
assay is also restricted to analysis of only hepatic transcriptional activity,
and additional studies are needed to determine whether variants that alter
in vitroABCG2 promoter activity in renal, intestinal, and breast cell lines
affect in vivo ABCG2 expression in those tissues.
Three of four variants in the ABCG2 promoter that altered promoter
activity in vitro have reported low minor allele frequencies. This is in
concordance with a large analysis of ABC and SLC (solute carrier) gene
Fig. 3. Effect of promoter variants in vivo. The luciferase activity in mouse liver
homogenates was measured 24 hours after plasmid injection. Promoter activity is
expressed as the ratio of firefly to Renilla luciferase activity normalized to empty
pGL4.11b activity. An enhancer for ApoE was used as the positive control (Simonet
et al., 1993). Data are expressed as box-and-whisker plots for four to five mice.
Differences between reference promoter or ApoE and pGL4.11b were tested by an
unpaired Student’s t test, †P , 0.05; reference and variant promoter sequences were
compared using a one-way ANOVA followed by a Bonferroni’s multiple-
comparison t test, *P , 0.05.
Fig. 4. Effect of rs76656413 and rs59370292 on DNA-protein binding. Represen-
tative electrophoretic mobility shift assay using HepG2 nuclear extracts incubated
with IRDye 700–labeled probes for reference and rs76656413 (A) or rs59370292
(B) sequences. Competition assays were performed with 40-fold excess unlabeled
oligonucleotides, with arrows indicating specific DNA/protein bands. Reference and
variant DNA sequences surrounding each nucleotide mutation (underlined) are shown
below their respective gel.
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promoter variation that found the proximal promoters of these gene
families had low nucleotide diversity (Hesselson et al., 2009) and global
genome analysis showing enrichment in promoters for rare variants
(Li et al., 2017). Due to the low frequency of these variants, it is difficult
to correlate them with the expression of ABCG2 and, thus, whether they
contribute significantly to population variability in ABCG2 expression
cannot be determined. Nonetheless, consistent with similar global rare
variant observations, these rare variants could have large effects on
expressionwithin individuals (Li et al., 2017). Further studies are needed
to examine in more detail the association of these variants with the
expression of ABCG2 and the function of the BCRP transporter in both
the liver and extrahepatic tissues important for xenobiotic disposition.
The ABCG2 promoter SNP rs76656413 had strong evidence for
altering the transcriptional activity of the ABCG2 promoter. It attenuated
the relative luciferase activity of the ABCG2 promoter by 50% in all four
cells lines and decreased ABCG2 liver promoter activity by 70% in vivo.
Transcription factor binding site analysis predicted rs76656413 to have
significant losses in upstream stimulatory factor-1 (USF-1), n-Myc,
myc-associated factor X (Max), and Myc-Max binding (data not shown)
that is consistent with its location in the middle of several USF-1 and
c-Myc ChIP-seq peaks reported by ENCODE. Not only does the SNP
fall in the middle of ChIP-Seq peaks, it is directly within a canonical
motif for both Myc and Max. Additionally, c-Myc and Max have been
reported to direct the transcriptional regulation of ABC genes, particu-
larly the unmethylated ABCG2 promoter, in human leukemic hemato-
poietic progenitor cells (Porro et al., 2011). Furthermore, the expression
of ABCG2 is altered by the overexpression of c-Myc in human breast
epithelial cells (Kang et al., 2009). Competition assays and transcription
factor supershift experiments based on the predicted binding of
transcription factors did not reveal changes in the binding of specific
transcription factors by the rs76656413 SNP. Further studies are needed
to confirm that USF-1, Max, and c-Myc transcription factors bind to the
ABCG2 promoter and that rs76656413 changes USF-1, Max, and/or
Myc binding, thus altering the transcriptional activity of the ABCG2
promoter.
The ABCG2 promoter SNP rs59370292, located just upstream of the
ARE, has the lowest reported MAF of the four variants that alter in vitro
ABCG2 promoter activity. It altered the relative luciferase activity of the
ABCG2 promoter in three of four cell lines and had the largest effect of
any ABCG2 promoter variant in vivo, decreasing the promoter activity
by 80%. EMSA showed reduced binding of nuclear liver extract to the
rs59370292 mutated probe. The transcription factor predicted to have
the largest reduced binding due to rs59370292 is the vitamin D receptor
(VDR; data not shown). Although VDR has not been directly linked to
ABCG2 expression, VDR is important in regulating bile acid trans-
porters, and its ligands include bile acid derivatives and steroids
(Germain et al., 2006; Halilbasic et al., 2013). Since ABCG2 encodes
a bile acid transporter (Blazquez et al., 2012) and has been shown to be
important for the pharmacokinetics and pharmacodynamics of statins
(Generaux et al., 2011), VDR could be the link for statin regulation of
ABCG2 expression. However, supershift or competition EMSAs were
not able to demonstrate a role for VDR, and further studies are needed to
determine whether VDR binding to the proximal promoter of ABCG2 is
involved in ABCG2 transcription.
In summary, the ABCG2 promoter (2499 to +21) had strong activity
in HCT116 and HEK293T cell lines and in vivo in the liver. The
rs76656413 and rs59370292 SNPs within the basal promoter of ABCG2
affect its function both in vitro and in vivo.We found these SNPs to have
altered transcription factor binding through EMSAs. Although their low
allele frequencies limit their impact on the population-level expression
of ABCG2, these and other rare variants in ABCG2 could be important
for regulating expression in individual patients.
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